Budesonide Patent Expiration
Budesonide is Used for long-term management of asthma in adults and children aged 6 and older, including those needing oral corticosteroids. It was first introduced by Astrazeneca Lp
Budesonide Patents
Given below is the list of patents protecting Budesonide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tarpeyo | US11896719 | Pharmaceutical compositions | Jan 23, 2043 | Calliditas |
| Tarpeyo | US12171882 | Pharmaceutical compositions | Jan 23, 2043 | Calliditas |
| Tarpeyo | US12171883 | Pharmaceutical compositions | Jan 23, 2043 | Calliditas |
| Tarpeyo | US12311057 | Pharmaceutical compositions | Jan 23, 2043 | Calliditas |
| Eohilia | US11260064 | Stable corticosteroid compositions | Jan 10, 2039 | Takeda Pharms Usa |
| Eohilia | US11564934 | Stable corticosteroid compositions | Jan 10, 2039 | Takeda Pharms Usa |
| Ortikos | US10172802 | Oral pharmaceutical dosage forms of budesonide | Sep 09, 2036 | Sun Pharm Inds Inc |
| Ortikos | US9707182 | Oral pharmaceutical dosage forms of budesonide | Sep 09, 2036 | Sun Pharm Inds Inc |
| Uceris | US10307375 | Controlled release and taste masking oral pharmaceutical composition | Sep 07, 2031 | Salix |
| Uceris | US10660858 | Controlled release and taste masking oral pharmaceutical composition | Sep 07, 2031 | Salix |
| Uceris | US8895064 | Controlled release and taste masking oral pharmaceutical composition | Sep 07, 2031 | Salix |
| Uceris | US9132093 | Controlled release and taste making oral pharmaceutical composition | Sep 07, 2031 | Salix |
| Uceris | US9192581 | Controlled release and taste masking oral pharmaceutical composition | Sep 07, 2031 | Salix |
| Eohilia | US8324192 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | Aug 03, 2029 | Takeda Pharms Usa |
| Eohilia | US9050368 | Corticosteroid compositions | Aug 01, 2029 | Takeda Pharms Usa |
| Tarpeyo | US8491932 | Compositions for the oral delivery of corticosteroids | May 07, 2029 | Calliditas |
| Eohilia | US10293052 | Compositions for the treatment of gastrointestinal inflammation | Nov 22, 2028 | Takeda Pharms Usa |
| Eohilia | US11357859 | Compositions for the treatment of gastrointestinal inflammation | Nov 12, 2028 | Takeda Pharms Usa |
| Eohilia | US11197822 | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract | Nov 09, 2026 | Takeda Pharms Usa |
| Eohilia | US11413296 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | Nov 09, 2026 | Takeda Pharms Usa |
| Eohilia | US8497258 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | Nov 09, 2026 | Takeda Pharms Usa |
| Eohilia | US8679545 | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract | Nov 09, 2026 | Takeda Pharms Usa |
| Eohilia | US8975243 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | Nov 09, 2026 | Takeda Pharms Usa |
| Eohilia | US9119863 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | Nov 09, 2026 | Takeda Pharms Usa |
| Uceris | US10064878 | Controlled release and taste masking oral pharmaceutical compositions |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US10105374 | Controlled release and taste masking oral pharmaceutical compositions |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US10143698 | Controlled release and taste masking oral pharmaceutical compositions |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US7410651 | Controlled release and taste masking oral pharmaceutical composition |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US7431943 | Controlled release and taste masking oral pharmaceutical compositions |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US8293273 | Controlled release and taste masking oral pharmaceutical composition |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US8784888 | Controlled release and taste masking oral pharmaceutical composition |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US9320716 | Controlled release and taste masking oral pharmaceutical compositions |
Jun 09, 2020
(Expired) | Salix |
| Uceris | US9532954 | Controlled release and taste masking oral pharmaceutical compositions |
Jun 09, 2020
(Expired) | Salix |
| Uceris | USRE43799 | Controlled release and taste masking oral pharmaceutical composition |
Jun 09, 2020
(Expired) | Salix |
| Pulmicort Respules |
US6598603 (Pediatric) | Method for treating respiratory diseases |
Jun 23, 2019
(Expired) | Astrazeneca |
| Pulmicort Respules |
US6899099 (Pediatric) | Method for treating a respiratory disease |
Jun 23, 2019
(Expired) | Astrazeneca |
| Pulmicort Respules |
US7524834 (Pediatric) | Sterile powders, formulations, and methods for producing the same |
May 11, 2019
(Expired) | Astrazeneca |
| Pulmicort Respules | US6598603 | Method for treating respiratory diseases |
Dec 23, 2018
(Expired) | Astrazeneca |
| Pulmicort Respules | US6899099 | Method for treating a respiratory disease |
Dec 23, 2018
(Expired) | Astrazeneca |
| Pulmicort Respules | US7524834 | Sterile powders, formulations, and methods for producing the same |
Nov 11, 2018
(Expired) | Astrazeneca |
| Pulmicort Flexhaler | US6142145 | Inhalation device |
May 08, 2018
(Expired) | Cheplapharm |
| Pulmicort Flexhaler | US7143764 | Inhalation device |
Mar 13, 2018
(Expired) | Cheplapharm |
| Pulmicort Flexhaler | US6027714 | Formulation for inhalation |
Jan 09, 2018
(Expired) | Cheplapharm |
| Pulmicort Flexhaler | US6287540 | Formulation for inhalation |
Jan 09, 2018
(Expired) | Cheplapharm |
| Rhinocort |
US6291445 (Pediatric) | Low dose budesonide formulations and uses thereof |
Oct 29, 2017
(Expired) | Astrazeneca |
| Rhinocort |
US6686346 (Pediatric) | Formulation |
Oct 29, 2017
(Expired) | Astrazeneca |
| Rhinocort |
US6986904 (Pediatric) | Formulation |
Oct 29, 2017
(Expired) | Astrazeneca |
| Rhinocort | US6291445 | Low dose budesonide formulations and uses thereof |
Apr 29, 2017
(Expired) | Astrazeneca |
| Rhinocort | US6686346 | Formulation |
Apr 29, 2017
(Expired) | Astrazeneca |
| Rhinocort | US6986904 | Formulation |
Apr 29, 2017
(Expired) | Astrazeneca |
| Uceris | US5914122 | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams |
Dec 19, 2015
(Expired) | Salix |
| Entocort Ec |
US5643602 (Pediatric) | Oral composition for the treatment of inflammatory bowel disease |
Jan 01, 2015
(Expired) | Padagis Us |
| Entocort Ec | US5643602 | Oral composition for the treatment of inflammatory bowel disease |
Jul 01, 2014
(Expired) | Padagis Us |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Budesonide's patents.
Latest Legal Activities on Budesonide's Patents
Given below is the list recent legal activities going on the following patents of Budesonide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Jan, 2025 | US8491932 |
| Expire Patent | 25 Nov, 2024 | US8293273(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 10 Jun, 2024 | US8293273(Litigated) |
| Expire Patent Critical
| 03 Jun, 2024 | US9320716 |
| Email Notification Critical
| 27 Mar, 2024 | US11896719 |
| Email Notification Critical
| 26 Mar, 2024 | US11896719 |
| Patent eCofC Notification | 26 Mar, 2024 | US11896719 |
| Mail Patent eCofC Notification | 26 Mar, 2024 | US11896719 |
| Recordation of Patent eCertificate of Correction | 26 Mar, 2024 | US11896719 |
| Post Issue Communication - Certificate of Correction | 05 Mar, 2024 | US11896719 |
Budesonide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Budesonide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
